Drug producer LaborMed, a part of Advent Internationalinvestment fund, expects its turnover to reach 150 million euros inthree years' time, compared with the 60 million euros forecast forthis year. "We intend to develop a regional company. Currently 10%of our sales are accounted for by exports, but they will reach 30%in no more than three years' time," said Adrian Stroilescu,business development director of LaborMed Group. The company hasconsolidated its presence on foreign markets after acquiring rivalOzone in July, currently operating in countries such as Poland, theCzech Republic, Slovakia, the Republic of Moldova and Russia. Ozonehad a regional portfolio that included 400 brands, such asAlgozone, Ceclozone, Entran, and ExtremVit.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
